Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.» Read More
California's Obamacare exchange gave UnitedHealth Group limited access to the state's individual insurance marketplace.
Millions of people are potentially eligible for exemptions from Obamacare taxes, but many won't apply for those waivers.
At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.
Top U.S. health official Marilyn Tavenner resigned as administrator of the Centers for Medicare and Medicaid Services Friday.
Here are three reasons why Obama's proposed federal law mandating paid sick leave from work would be a bad idea.
Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
An increasing number of people said they failed to get health insurance last year because they didn't know how to apply.
The number of people financially strapped by medical costs has decreased on the heels of the rollout of key Obamacare programs, a new study finds.
The New York Times reports that a tightfisted government imposes very real costs, especially for those benefiting from Medicaid. The NYT reports.
Executives at J.P. Morgan's healthcare conference discuss the technologies they believe with change medicine as we know it.
Every state served by the federal Obamacare exchange has already topped the sign-up level that they reached last year.
California's Obamacare exchange has signed up 217,000 new customers, but plans to get more by warning uninsured people about increasing fines.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.
Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.
Vertex CEO Dr. Jeffrey Leiden tells CNBC's Meg Tirrell about the company's new drug trials and focus areas in 2015.
"Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.
Mike Narachi, Orexigen CEO, speaks with CNBC's Meg Tirrell about its obesity drug and program.
Hans Bishop, Juno Therapeutics co-founder and CEO, discusses promising data for new cancer immunotherapy approaches.
Get the best of CNBC in your inbox